Literature DB >> 6112296

S100 protein: a marker for human malignant melanomas?

R Gaynor, H R Herschman, R Irie, P Jones, D Morton, A Cochran.   

Abstract

S100 protein is a nervous-system-specific cytoplasmic protein which is also present in human malignant melanoma cell lines. To test for its tumour specificity, biopsy specimens from normal tissue and a wide variety of tumours were tested for S100 by complement fixation and immunofluorescence tests. S100 was present in all of thirteen samples of malignant melanoma tissue and absent from nineteen samples of non-melanocytic tumours, and from normal skin and normal lymph nodes. S100 levels did not correlate with tyrosinase activity in the tissues examined. Detection and measurement of S100 protein may help distinguish poorly differentiated amelanotic malignant melanoma from tumours of obscure histological origin; they may also aid the detection of micrometastatic disease in the lymph nodes and other tissues of melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112296     DOI: 10.1016/s0140-6736(81)92142-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  Diagnostic immunopathology.

Authors:  P A Cancilla; A J Cochran; F Naeim; J W Said
Journal:  West J Med       Date:  1986-07

2.  Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.

Authors:  T Bánfalvi; K Gilde; M Boldizsár; T Kremmer; S Ottó
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 3.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

4.  Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas.

Authors:  V Wagner; J Rudi; H Näher; W Stremmel
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

5.  Detection of S-100 protein in melanocytic and neurogenic cutaneous tumors.

Authors:  H Yambe; Y Ishii; K Tabuchi; T Isobe; K Kikuchi
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

Review 6.  The evolution of S100B inhibitors for the treatment of malignant melanoma.

Authors:  Kira G Hartman; Laura E McKnight; Melissa A Liriano; David J Weber
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

7.  S-100 protein stimulates cellular proliferation.

Authors:  J R Klein; D S Hoon; J Nangauyan; E Okun; A J Cochran
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid.

Authors:  C J Sindic; M P Chalon; C L Cambiaso; E C Laterre; P L Masson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

9.  The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas. A comparative study using S-100 and neuron-specific enolase antibodies.

Authors:  D R Springall; J Gu; D Cocchia; F Michetti; A Levene; M M Levene; P J Marangos; S R Bloom; J M Polak
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

10.  Hypersensitivity to human brain S-100 protein in chronic alcoholics.

Authors:  B D Janković; S Jakulić; J Horvat
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.